Covered recipient · General Payments record
EMILY MAE WOODS
Allopathic & Osteopathic Physicians Obstetrics & Gynecology
General Payments · PY2021–2024
$921.27
- Reported across 39 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $528.51 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $182.99 | 5 |
| Abbott Laboratories | $144.13 | 1 |
| Sumitomo Pharma America, Inc. | $64.97 | 3 |
| Organon LLC | $61.51 | 4 |
| Astellas Pharma US Inc | $21.49 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $20.50 | 1 |
| Aspira Women's Health Inc | $18.47 | 1 |
| PFIZER INC. | $14.45 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $144.13 | 05/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125362838 | CMS |
| Amgen Inc. | $17.45 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111742118 | CMS |
| Amgen Inc. | $15.49 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111742120 | CMS |
| Amgen Inc. | $121.36 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111742126 | CMS |
| Amgen Inc. | $10.70 | 06/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111742122 | CMS |
| Amgen Inc. | $17.99 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111742124 | CMS |
| Aspira Women's Health Inc | $18.47 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126781208 | CMS |
| Astellas Pharma US Inc | $21.49 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139276658 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $20.50 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086114108 | CMS |
| Organon Llc | $14.35 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136239670 | CMS |
| Organon Llc | $14.72 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136239677 | CMS |
| Organon Llc | $13.95 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136239673 | CMS |
| Organon Llc | $18.49 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136239681 | CMS |
| PFIZER INC. | $14.45 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131075131 | CMS |
| Sumitomo Pharma America, Inc. | $13.37 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148937211 | CMS |
| Sumitomo Pharma America, Inc. | $25.99 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148937213 | CMS |
| Sumitomo Pharma America, Inc. | $25.61 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148937215 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.